Ionis Pharmaceuticals (NASDAQ:IONS) EVP Shannon Devers Sells 16,777 Shares

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Shannon Devers sold 16,777 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $80.91, for a total transaction of $1,357,427.07. Following the completion of the transaction, the executive vice president directly owned 17,494 shares in the company, valued at $1,415,439.54. This represents a 48.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ionis Pharmaceuticals Stock Up 0.1%

NASDAQ IONS traded up $0.05 on Friday, reaching $82.75. 852,943 shares of the stock traded hands, compared to its average volume of 2,072,262. The company has a market cap of $13.40 billion, a price-to-earnings ratio of -48.96 and a beta of 0.33. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.86 and a current ratio of 2.87. Ionis Pharmaceuticals, Inc. has a 12 month low of $23.95 and a 12 month high of $82.95. The company has a fifty day moving average price of $71.28 and a 200-day moving average price of $52.38.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.35. The firm had revenue of $156.72 million during the quarter, compared to analysts’ expectations of $131.75 million. Ionis Pharmaceuticals had a negative net margin of 26.45% and a negative return on equity of 45.29%. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.95) EPS. Ionis Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Golden State Wealth Management LLC boosted its stake in shares of Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock valued at $25,000 after buying an additional 250 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $25,000. Mather Group LLC. purchased a new position in Ionis Pharmaceuticals in the third quarter worth approximately $27,000. Quarry LP acquired a new position in Ionis Pharmaceuticals during the 3rd quarter worth approximately $38,000. Finally, Johnson Financial Group Inc. acquired a new position in Ionis Pharmaceuticals during the 3rd quarter worth approximately $44,000. Institutional investors and hedge funds own 93.86% of the company’s stock.

Analyst Upgrades and Downgrades

IONS has been the topic of several research analyst reports. Raymond James Financial reiterated a “strong-buy” rating and set a $89.00 price target (up previously from $85.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, October 30th. HC Wainwright raised their target price on Ionis Pharmaceuticals from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Royal Bank Of Canada upped their price target on Ionis Pharmaceuticals from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Wall Street Zen downgraded Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Finally, Guggenheim boosted their price objective on Ionis Pharmaceuticals from $90.00 to $92.00 and gave the company a “buy” rating in a research report on Tuesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $84.15.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.